DE60025905D1 - In vitro methode zur synchronisation von oozytenreifung - Google Patents

In vitro methode zur synchronisation von oozytenreifung

Info

Publication number
DE60025905D1
DE60025905D1 DE60025905T DE60025905T DE60025905D1 DE 60025905 D1 DE60025905 D1 DE 60025905D1 DE 60025905 T DE60025905 T DE 60025905T DE 60025905 T DE60025905 T DE 60025905T DE 60025905 D1 DE60025905 D1 DE 60025905D1
Authority
DE
Germany
Prior art keywords
synchronization
vitro method
oxygen treatment
oxygen
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60025905T
Other languages
English (en)
Other versions
DE60025905T2 (de
Inventor
Christian Grondahl
Host Hansen
Alexander Ruebig
Christa Hegele-Hartung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Application granted granted Critical
Publication of DE60025905D1 publication Critical patent/DE60025905D1/de
Publication of DE60025905T2 publication Critical patent/DE60025905T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0608—Germ cells
    • C12N5/0609—Oocytes, oogonia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C12N2501/392—Sexual steroids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/10—Conditioning of cells for in vitro fecondation or nuclear transfer
DE60025905T 1999-02-24 2000-02-23 In vitro methode zur synchronisation von oozytenreifung Expired - Fee Related DE60025905T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DK25599 1999-02-24
DKPA199900255 1999-02-24
US13081699P 1999-04-23 1999-04-23
US130816P 1999-04-23
DKPA199901310 1999-09-16
DK131099 1999-09-16
PCT/DK2000/000074 WO2000050066A1 (en) 1999-02-24 2000-02-23 Treatment of infertility

Publications (2)

Publication Number Publication Date
DE60025905D1 true DE60025905D1 (de) 2006-04-20
DE60025905T2 DE60025905T2 (de) 2006-09-14

Family

ID=27220546

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60025905T Expired - Fee Related DE60025905T2 (de) 1999-02-24 2000-02-23 In vitro methode zur synchronisation von oozytenreifung

Country Status (13)

Country Link
US (1) US6585982B1 (de)
EP (1) EP1156822B1 (de)
JP (1) JP2002537349A (de)
KR (1) KR20010093280A (de)
CN (1) CN1353617A (de)
AT (1) ATE317266T1 (de)
AU (1) AU2794100A (de)
BR (1) BR0008468A (de)
CZ (1) CZ20012967A3 (de)
DE (1) DE60025905T2 (de)
ES (1) ES2258445T3 (de)
HU (1) HUP0200157A3 (de)
WO (1) WO2000050066A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
WO2000052142A2 (en) * 1999-02-26 2000-09-08 Novo Nordisk A/S Culture medium comprising meiosis activating sterols (mas) and method for in vitro fertilisation
WO2001062260A2 (en) * 2000-02-25 2001-08-30 Schering Aktiengesellschaft Improvement of implantation rate
EP1257279A2 (de) * 2000-02-25 2002-11-20 Schering Aktiengesellschaft Verbesserung von implantierungsrate mit ff-mas
AU2001263924A1 (en) * 2000-05-18 2001-11-26 Novo-Nordisk A/S Fertilization of aged oocytes
EP1287033A2 (de) * 2000-05-25 2003-03-05 Queen's University At Kingston Sperma protein pt32, c-yes aus spermien und cytoplasma von oozyten, sowie verwendung dieser proteine
EP1216701A1 (de) * 2000-12-22 2002-06-26 Schering Aktiengesellschaft Verfahren zur Erhöhung der Konzentration von Meiosis-aktivierenden Sterolen in der Cholesterolsynthese und die Verwendung von potenten Hemmstoffen in das Verfahren
EP1245572A1 (de) 2001-03-26 2002-10-02 Schering Aktiengesellschaft Aminosterol-Verbindungen, ihre Verwendung zur Herstellung Meiose-regulierender Medikamenten und ein Vefahren zu ihrer Herstellung
AU2002324183B2 (en) * 2001-09-12 2007-10-25 Merck Serono Sa Use of hCG and LH in controlled ovarian hyperstimulation
DE60238490D1 (de) 2001-09-12 2011-01-13 Merck Serono Sa Verwendung von humanem choriongonadotropin (hcg) und luteinisierendem hormon (lh) zur regulierten hyperstimulation der eierstöcke
CA2457849A1 (en) 2001-09-12 2003-03-20 Applied Research Systems Ars Holding N.V. Use of hcg in controlled ovarian hyperstimulation
WO2003070766A2 (en) * 2002-02-22 2003-08-28 Novo Nordisk A/S A transducer of mas signalling
EP1483368A2 (de) 2002-03-08 2004-12-08 McGill University In vitro reifung unreifer humaner oozyten
KR20050058285A (ko) * 2002-06-07 2005-06-16 아레스 트레이딩 에스.에이. 조절된 난소 과자극 방법 및 이런 방법에 이용되는제약학적 키트
SI1765085T1 (sl) 2004-05-17 2015-11-30 The General Hospital Corporation Sestavki, ki vsebujejo ženske zarodne matične celice in postopki njihove uporabe
MY154677A (en) 2006-03-07 2015-07-15 Shroff Geeta Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
EP2787073B1 (de) 2011-04-14 2019-03-20 The General Hospital Corporation Zusammensetzungen und verfahren zur übertragung der energie autologer keimbahn-mitochondrien
CN103827293A (zh) 2011-06-29 2014-05-28 通用医疗公司 用于增强雌性生殖细胞中生物能状态的组合物和方法
US20150272622A1 (en) 2011-12-22 2015-10-01 Previvo Genetics, Llc Recovery and processing of human embryos formed in vivo

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5563059A (en) * 1993-02-23 1996-10-08 Genentech, Inc. Use of human inhibin and human activin to increase the number of mature primate oocytes
US5716777A (en) * 1994-06-23 1998-02-10 Novo Nordisk A/S Regulation of meiosis using sterols
CA2214126A1 (en) * 1995-03-06 1996-09-12 Novo Nordisk A/S Stimulation of meiosis
AU6122696A (en) * 1995-06-23 1997-01-22 Novo Nordisk A/S Meiosis regulating compounds
BR9608968A (pt) * 1995-06-23 1999-06-29 Novo Nordisk As Composto e processo para regular meiose em uma célula germinativa de mamífero
DE69721304T2 (de) * 1996-12-20 2004-03-04 Novo Nordisk A/S Verbindungen zur Regulierung der Meiose
DE69804611T2 (de) * 1997-06-04 2002-10-02 Akzo Nobel Nv 17-beta.-allyloxy(thio)alkyl-androstan derivative zur modulation von meiose
US5866599A (en) * 1997-06-06 1999-02-02 Basf Aktiengesellschaft Fungicidal mixtures
ATE361091T1 (de) * 1999-02-24 2007-05-15 Novo Nordisk As Behandlung von unfruchtbarkeit

Also Published As

Publication number Publication date
DE60025905T2 (de) 2006-09-14
HUP0200157A3 (en) 2002-06-28
BR0008468A (pt) 2002-02-05
CZ20012967A3 (cs) 2001-12-12
US6585982B1 (en) 2003-07-01
HUP0200157A2 (hu) 2002-05-29
CN1353617A (zh) 2002-06-12
WO2000050066A1 (en) 2000-08-31
ATE317266T1 (de) 2006-02-15
JP2002537349A (ja) 2002-11-05
AU2794100A (en) 2000-09-14
KR20010093280A (ko) 2001-10-27
EP1156822B1 (de) 2006-02-08
ES2258445T3 (es) 2006-09-01
EP1156822A1 (de) 2001-11-28

Similar Documents

Publication Publication Date Title
DE60025905D1 (de) In vitro methode zur synchronisation von oozytenreifung
HK1085140A1 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
ATE361977T1 (de) In vitro verfahren zur induzierung der regulierten pankreatische-hormon produktion in nicht-pankreatischen inselngeweben, damit verbundene pharmazeutische zusammenseztzungen
DE60114002D1 (de) VERFAHREN ZUR HERSTELLUNG KRISTALLINEr PARTIKEL ZUR INHALATION
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
SG148217A1 (en) Method for treating adamts-5-associated disease
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
BR0109975A (pt) Método para produzir ansamitocinas
TW200407133A (en) Novel PPARα and PPARγ agonists
NO984950L (no) Forbindelser med veksthormonfrigj°rende egenskaper
GB9907571D0 (en) Compounds
UA83203C2 (uk) Тіазол-(бі)циклоалкілкарбоксаніліди, засіб на їх основі та застосування для боротьби з небажаними мікроорганізмами
DE60039160D1 (de) Verwendung von erbb-rezeptorliganden zur behandlung von diabetes
ATE252383T1 (de) Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
IS5380A (is) Aðferð til framleiðslu á vaxtarhormón seyti
ATE306942T1 (de) Zusammensetzung zur in-vitro befruchtung
ATE446952T1 (de) Herstellungsverfahren von 2-cyanopyridinen
MY127328A (en) 5-amino-1-pentene-3-ol substituted derivatives
NO20015285L (no) Fremstillingsprosess for n¶ringsmiddelfermenterende midler
ATE537160T1 (de) Verfahren zur herstellung von 14beta- hydroxybaccatin-iii-1,14-carbonat
ATE466847T1 (de) Verfahren zur herstellung von 14-beta- hydroxybaccatin-iii-1,14-carbonat
DE50011342D1 (de) Polycarbonat-substrate
EE200100242A (et) Alfa-arüülalkaanhapete valmistamismeetod
EP1146866A4 (de) Behandlungsmethode von aknepatienten durch verabreichung von hemmern der cyclischen gmp pde
DE60211677D1 (de) Verfahren zur herstellung von 2-hydroxymethyl-pyrolidin-3,4-diolen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee